Showing 2762 results
- Featured News /Novartis announced the company’s financial results for the third quarter of 2020.
- Media Library /
- Media Library /
- Media Library /
- Featured News /
Novartis poised to expand impact on human health as it begins next era.
- Media Release /Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare…
- Media Release /Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic…
- Media Release /
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface painDeal consistent with Novartis focused strategy of… - Media Release /Cosentyx® (secukinumab) is the first new biologic treatment for hidradenitis suppurativa (HS) in nearly a decade, offering clinically meaningful results across the most debilitating symptoms1,2…
Pagination
- ‹ Previous page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- …
- 277
- › Next page